AIA Group Ltd Increases Stock Position in Gilead Sciences, Inc. $GILD

AIA Group Ltd raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 68.3% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 46,372 shares of the biopharmaceutical company’s stock after buying an additional 18,826 shares during the period. AIA Group Ltd’s holdings in Gilead Sciences were worth $5,147,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. Norges Bank purchased a new position in Gilead Sciences during the second quarter worth approximately $2,150,268,000. Ameriprise Financial Inc. grew its stake in Gilead Sciences by 397.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock valued at $748,147,000 after acquiring an additional 5,392,191 shares during the period. Invesco Ltd. grew its stake in Gilead Sciences by 33.5% in the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after acquiring an additional 3,394,330 shares during the period. Assenagon Asset Management S.A. increased its holdings in Gilead Sciences by 164.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock worth $387,286,000 after acquiring an additional 2,169,266 shares in the last quarter. Finally, First Trust Advisors LP raised its position in Gilead Sciences by 154.3% during the third quarter. First Trust Advisors LP now owns 3,089,283 shares of the biopharmaceutical company’s stock worth $342,910,000 after acquiring an additional 1,874,508 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Down 0.1%

GILD stock opened at $141.11 on Friday. Gilead Sciences, Inc. has a one year low of $93.37 and a one year high of $157.29. The firm has a market cap of $175.18 billion, a PE ratio of 20.84, a PEG ratio of 1.85 and a beta of 0.37. The firm’s 50 day moving average price is $142.36 and its 200-day moving average price is $127.60. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.83 by $0.03. The company had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same period in the prior year, the business posted $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be given a $0.82 dividend. The ex-dividend date of this dividend is Friday, March 13th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a yield of 2.3%. Gilead Sciences’s dividend payout ratio is currently 48.45%.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Wall Street Zen raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 14th. Oppenheimer upped their price target on shares of Gilead Sciences from $128.00 to $165.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 11th. Royal Bank Of Canada raised their price target on shares of Gilead Sciences from $103.00 to $118.00 and gave the company a “sector perform” rating in a research note on Wednesday, February 11th. Scotiabank lifted their price objective on Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a report on Wednesday, February 11th. Finally, BMO Capital Markets boosted their price objective on Gilead Sciences from $135.00 to $150.00 and gave the stock an “outperform” rating in a research note on Monday, January 26th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and a consensus target price of $157.62.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the completion of the sale, the insider directly owned 120,288 shares in the company, valued at $18,577,278.72. This trade represents a 18.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $144.23, for a total transaction of $432,690.00. Following the completion of the sale, the chief financial officer directly owned 179,191 shares in the company, valued at $25,844,717.93. This trade represents a 1.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 309,280 shares of company stock worth $44,068,850. 0.27% of the stock is owned by corporate insiders.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Pipeline boost — Assembly Biosciences licensed a helicase‑primase inhibitor program (including candidates ABI‑5366 and ABI‑1179) to Gilead after positive Phase 1b interim data, adding early‑stage herpes assets to Gilead’s antiviral franchise and expanding near‑term development options. This is a clear pipeline + inorganic expansion signal. Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights
• Positive Sentiment: Analyst support — Multiple firms have raised targets or maintain buy ratings (Deutsche Bank, Jefferies, BofA, Needham), lifting consensus target above the current trade and providing institutional buying ammunition. This helps underpin the shares despite short‑term weakness.
• Positive Sentiment: Shareholder return signal — Gilead recently raised its quarterly dividend to $0.82 (ann. $3.28), reinforcing cash‑flow confidence and appeal to income investors. Dividend / SEC Filing
• Neutral Sentiment: Trending attention / coverage — Zacks and other outlets flagged GILD as a trending stock; that can increase intraday volume and volatility but doesn’t indicate fundamental change. Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
• Neutral Sentiment: Market‑flow signals — Unusual options activity and recent coverage pieces on valuation have attracted attention; these can amplify swings but are ambiguous for direction until large trades or analyst revisions follow. 2 Mega-Cap Nasdaq Stocks with Unusual Options Activity: What to Watch
• Negative Sentiment: Insider selling — Recent disclosed sales (including Johanna Mercier and a reported sale by the CFO) have been highlighted in filings and press summaries; insider sales can weigh on sentiment even when they’re routine or pre‑planned. Insider Sale – Johanna Mercier CFO SEC Filing

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.